Predictive Biomarkers for Adjuvant Capecitabine Benefit in Early-Stage Triple-Negative Breast Cancer in the FinXX Clinical TrialKarama Asleh, Saranya Chumsri, Heather Ann Brauer et al.|Clinical Cancer Research|2020Cited by 41
Effects of immune architecture on response to adjuvant capecitabine in triple-negative breast cancer (FinXX trial).Saranya Chumsri, E. Aubrey Thompson, Karama Asleh et al.|Journal of Clinical Oncology|2019Cited by 1
Abstract P3-11-05: Predictive gene signatures of adjuvant capecitabine benefit in triple negative breast cancer in the FinXX trialSaranya Chumsri, E. Aubrey Thompson, Karama Asleh et al.|Cancer Research|2019Cited by 1
Supplementary Figure S4 from Predictive Biomarkers for Adjuvant Capecitabine Benefit in Early-Stage Triple-Negative Breast Cancer in the FinXX Clinical TrialKarama Asleh, Saranya Chumsri, Heather Ann Brauer et al.|Unknown|2023Cited by 0
Supplementary Figure S2 from Predictive Biomarkers for Adjuvant Capecitabine Benefit in Early-Stage Triple-Negative Breast Cancer in the FinXX Clinical TrialKarama Asleh, Saranya Chumsri, Heather Ann Brauer et al.|Unknown|2023Cited by 0